NORCROSS, Ga., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company's abstract titled "Early phase 1 clinical trial results of GR-MD-02, a galectin-3 inhibitor, in patients having non-alcoholic steatohepatitis (NASH) with advanced fibrosis" was accepted as an oral presentation at The Liver Meeting, the 65th Annual Meeting of the American Association for the Study of Liver Diseases. The presentation will be made on Sunday, November 9, 2014 at 3:30pm Eastern Standard Time
at the Hynes Convention Center in Boston, Mass.
Stephen A. Harrison, MD, Chief of Hepatology at Brooke Army Medical Center in San Antonio, Texas, will present the data during a session titled "Parallel 8: Novel Approaches in Diagnosis and Treatment in NAFLD and NASH." Dr. Harrison is a clinical trial investigator in Galectin Therapeutics' ongoing Phase 1 clinical trial of GR-MD-02 in NASH (fatty liver disease) patients with advanced fibrosis. The data presented will include the completed cohorts 1 and 2 of the Phase 1 trial and interim results of cohort 3.
According to Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc., "NASH with fibrosis is a significant unmet medical need for which effective therapies are limited. Acceptance of our data for an oral presentation at AASLD highlights the scientific and medical communities' deep interest in learning about new potential therapies for liver disease. We believe that GR-MD-02, our proprietary galectin-3 inhibitor, holds immense promise as a treatment option for fibrosis and inflammation."
The abstract is available at www.aasld.org.
About Galectin Therapeutics
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Forward-Looking Statements
This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding potential therapeutic benefits of our drugs, and expectations regarding the company's drug development program. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, our current drug development efforts may not lead to positive outcomes or regulatory approval. We may
experience delays in our trials, which could include enrollment delays. Future phases or future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to further develop and/or fund any studies or trials. We are currently the subject of litigation, which may impact our human and capital resources. To date, we have incurred operating losses since our inception, and our future success may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional
factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
CONTACT: Galectin Therapeutics Inc.
Peter G. Traber, MD, 678-620-3186
President, CEO, & CMO
ir@galectintherapeutics.com
Source:
Galectin Therapeutics, Inc.
News Provided by Acquire Media
